Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1313-1319

  Gan, Yuebo ^a   Mo, Yiqun ^a   Kalns, John E ^a   Lu, Jie ^a   Danenberg, Katherine ^c   Danenberg, Peter ^c   Wientjes, M Guill ^a,b   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CELL DNA; CYTOCHROME P450 REDUCTASE; MESSENGER RNA; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 0034902347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Intravesical chemotherapy: Treatment selection, techniques, and results
2. Intravesical therapy, a critical review
3. Pharmacodynamics of mitomycin C in cultured human bladder tumors
4. Penetration of mitomycin C in human bladder
5. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer
6. Integrated pharmacokinetic and pharmacodynamic studies to improve intravesical treatment of bladder cancer
7. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology
8. Reductive mechanism and alkylating activity of mitomycin C induced by rat liver microsomes
9. Bioreductive activation of mitomycin C by DT-diaphorase
10. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines
11. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: Advanced tumors express greater levels of DT-diaphorase
12. Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions
13. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression
14. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line
15. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C
16. Regulation of human NAD(P)H: Quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element
17. Involvement of NF-κB in the induction of NAD(P)H: Quinone oxidoreductase (DT-diaphorase) by hypoxia, altipraz and mitomycin C
18. Current issues in the enzymology of mitomycin C metabolic activation
19. Characterization of a polymorphism in NAD(P)H: Quinone oxidoreductase (DT-diaphorase)
20. NAD(P)H: Quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
21. Non-enzymatic and enzymatic activation of mitomycin activity
22. Decreased NADPH: Cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
23. Activation of mitomycin C by NADPH: Cytochrome P-450 reductase
24. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines
25. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture
26. Sponge-gel-supported histoculture drug-response assay for head and neck cancer
27. Potential of the histoculture drug-response assay to contribute to cancer patient survival
28. The clinical applications of the histoculture drug response assay
29. Pharmacodynamics of doxorubicin in human bladder tumors
30. Pharmacologic effects of paclitaxel in human bladder tumors
31. Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors
32. Technical aspects of quantitative competitive PCR
33. Increase of NAD-(P)H: Quinone reductase by dietary antioxidants: Possible role in protection against carcinogenesis and toxicity
34. Comparison of the Akaike Information Criterion, the Schwartz criterion and the F test as guides to model selection
35. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation between sensitivity to mitomycin C and EO9
36. DT-diaphorase in activation and detoxification of quinones